Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Despite increasing treatment options for this disease, prognosis remains poor. Our research projects are embedded in the medical research profile Cancer Pathogenesis and Therapy and focus on determination of factors associated with aggressive biologic behaviour of HCC, in order to better define optimal treatment options. Clinical and translational research is aimed at identification of and modifying aggressive biologic behaviour of hepatocellular in collaboration with the Dutch Hepatocellular Carcinoma Group, the Department of Radiology at the LUMC, Dutch Liver Transplant centres and University Hospital Bern. For future research a Dutch National HCC and Cholangiocarcinoma biobank and database will be set up by the DHCG embedded in the Parelsnoer Initiative, coordinated by the LUMC and funded by the Dutch Cancer Society.
Biosketch Minneke Coenraad
Minneke Coenraad MD PhD is gastroenterologist –hepatologist since 2007 at the Leiden University Medical Center, Leiden, The Netherlands. After graduating cum laude as medical doctor, she completed her specialization in Internal Medicine (2004) and subsequently in Gastroenterology-Hepatology (2007). She obtained her PhD in 2009. Her clinical focus is on cirrhosis, hepatocellular carcinoma and liver transplantation.
She is actively involved in scientific research in the field of complications of end-stage liver disease, specifically acute on chronic liver failure (ACLF) and hepatocellular carcinoma (HCC). Her main focus in ACLF is on hemodynamics and the interrelationship with inflammation. In HCC her research is focused on determination of factors associated with aggressive biologic behaviour of tumors and optimizing treatment. She is study director of an ongoing European multicentre study on the cost-effectiveness of hemodynamic monitoring of nonselective betablockers in patients with cirrhosis and principal investigator of an EU-funded European multicentre study on MRI imaging in patients after liver transplantation.
Coenraad is chairman of the Dutch Flemish Liver Week and board member of the Netherlands Association for the Study of the Liver from 2012-2018. She is chairman of the national biobank working group of the Dutch Hepatocellular & Cholangiocarcinoma Group. She is board member of the Dutch Portal Hypertension working group. She is member of the European Foundation for the study of Chronic liver failure.
Selected publications Coenraad
1. Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. J Pathol. 2018 Mar 31. doi: 10.1002/path.5083.
2. Coenraad MJ, Porcher R, Bendtsen F. Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: It takes three to tango. J Hepatol. 2018 May;68(5):887-889. doi: 10.1016/j.jhep.2018.02.007.
3. Solà E*, Kerbert AJ*, Verspaget HW, Moreira R, Pose E, Ruiz P, Cela R, Morales-Ruiz M, López E, Graupera I, Solé C, Huelin P, Navarro AA, Ariza X, Jalan R, Fabrellas N, Benten D, de Prada G, Durand F, Jimenez W, van der Reijden JJ, Fernandez J, van Hoek B, Coenraad MJ*, Ginès P*. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. J Hepatol. 2016 Nov;65(5):914-920. doi: 10.1016/j.jhep.2016.07.003. * contributed equally.
4. Clària J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, Amorós À, Titos E, Alcaraz-Quiles J, Oettl K, Morales-Ruiz M, Angeli P, Domenicali M, Alessandria C, Gerbes A, Wendon J, Nevens F, Trebicka J, Laleman W, Saliba F, Welzel TM, Albillos A, Gustot T, Benten D, Durand F, Ginès P, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF). Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology. 2016 Oct;64(4):1249-64.